Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,751 active trials43 approved drugs423 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Clinical trials
9,697 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,318)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06220214 | Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer | recruiting | Early Phase 1 | 30 | Alison StopeckOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07340424 | A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer. | recruiting | Early Phase 1 | 15 | Xiaorong SunOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07341360 | Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei(Pseudovax) | recruiting | Early Phase 1 | 10 | Oslo University HospitalOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05336266 | A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma(KetoROCX) | active not recruiting | Early Phase 1 | 28 | Andrew Hendifar, MDOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03511196 | Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer | active not recruiting | Early Phase 1 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06008275 | Neratinib in Combination With Ruxolitinib in Patients With mTNBC | recruiting | Early Phase 1 | 20 | Baylor Research InstituteOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT02111941 | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Early Phase 1 | 19 | Mayo ClinicOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT04049227 | Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer | completed | Early Phase 1 | 27 | Northwestern UniversityOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT04712721 | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. | terminated | Early Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 10, 2025 | clinicaltrials |
| NCT04857684 | SBRT + Atezolizumab + Bevacizumab in Resectable HCC | active not recruiting | Early Phase 1 | 20 | Massachusetts General HospitalOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07201064 | A Study of SZ1003 Injection in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 12 | Guangdong ProCapZoom Biosciences Co., Ltd.INDUSTRY | 0 | Oct 1, 2025 | clinicaltrials |
| NCT06273852 | A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors | completed | Early Phase 1 | 8 | Pure Biologics S.A.INDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06700070 | A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors | recruiting | Early Phase 1 | 12 | Pure Biologics S.A.INDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07113977 | Clinical Study of a Novel Humanized CD70-Targeted CAR-T Cell Incorporating TLR2 for Advanced Renal Cell Carcinoma Therapy | not yet recruiting | Early Phase 1 | 30 | Wei GuanOTHER | 0 | Aug 11, 2025 | clinicaltrials |
| NCT06246786 | Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer) | withdrawn | Early Phase 1 | 0 | Virginia G. KaklamaniOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07034742 | Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer | recruiting | Early Phase 1 | 136 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06383520 | Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma | recruiting | Early Phase 1 | 100 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT02671552 | Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery | withdrawn | Early Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT02896907 | Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery | completed | Early Phase 1 | 8 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06092112 | A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma | completed | Early Phase 1 | 2 | Shanghai Changzheng HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT06418659 | A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients | recruiting | Early Phase 1 | 37 | Shanghai Changzheng HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05250895 | BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy | completed | Early Phase 1 | 9 | Emory UniversityOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04906382 | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer | terminated | Early Phase 1 | 2 | Floor Backes, MDOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03473730 | Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer | completed | Early Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT01821612 | Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer | completed | Early Phase 1 | 23 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05289648 | Niraparib in High-grade Endometrial Cancer Trial(NIREC) | withdrawn | Early Phase 1 | 0 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 0 | Dec 19, 2024 | clinicaltrials |
| NCT03473691 | Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer(Breast50) | withdrawn | Early Phase 1 | 0 | University of VirginiaOTHER | 0 | Dec 9, 2024 | clinicaltrials |
| NCT06652243 | Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma(SN301A) | recruiting | Early Phase 1 | 12 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06646783 | Phase IIT Trial of SNA014 | not yet recruiting | Early Phase 1 | 28 | SmartNuclide BiopharmaINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06645314 | Study on the Safety and Efficacy of BST06 Injection in the Treatment of Advanced Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 16 | BioSyngen Pte LtdINDUSTRY | 0 | Oct 16, 2024 | clinicaltrials |
| NCT06619886 | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor | not yet recruiting | Early Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04310540 | PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer | completed | Early Phase 1 | 42 | Mayo ClinicOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03970252 | Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer | completed | Early Phase 1 | 28 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06428708 | [18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma | unknown | Early Phase 1 | 30 | Western UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04752267 | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases | completed | Early Phase 1 | 10 | University of Southern CaliforniaOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT06364800 | Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody | not yet recruiting | Early Phase 1 | 18 | Beijing 302 HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT03361800 | Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC | terminated | Early Phase 1 | 5 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT03812562 | Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection | terminated | Early Phase 1 | 2 | Northwestern UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer | withdrawn | Early Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT05070156 | B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma | unknown | Early Phase 1 | 3 | Tongji UniversityOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT03395847 | Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma | completed | Early Phase 1 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05111314 | Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma | withdrawn | Early Phase 1 | 0 | Mayo ClinicOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05436808 | Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer | withdrawn | Early Phase 1 | 0 | Stony Brook UniversityOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT03599453 | Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer | completed | Early Phase 1 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | May 6, 2023 | clinicaltrials |
| NCT04857697 | Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer | completed | Early Phase 1 | 6 | Mayo ClinicOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05093920 | Role of DEB-TACE Versus c-TACE in Treatment of HCC | unknown | Early Phase 1 | 30 | Sohag UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT04150874 | Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE | terminated | Early Phase 1 | 4 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT04976257 | Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion | completed | Early Phase 1 | 5 | Ryan Kohlbrenner, MDOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT04777708 | BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer | terminated | Early Phase 1 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 24, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Jan 15, 2026source: clinicaltrials